LONDON and PHILADELPHIA – February 18, 2026 – Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announces the executive management team will participate in the TD Cowen Investor Conference in March.
Christina Coughlin, CEO and Brian Hahn, CFO of Avacta, will participate in the 46th Annual TD Cowen Health Care Conference in Boston on March 3, 2026. The company will host investor meetings throughout the day, with a live Company presentation at 9:10 AM ET. Investors interested in accessing the Company’s presentation may view the replay of the presentation, which will be available after the event on the Investor Resources | Avacta Therapeutics site.